A MDP Model for Breast and Ovarian Cancer Intervention Strategies for BRCA1/2 Mutation Carriers

被引:15
|
作者
Abdollahian, Mehrnaz [1 ]
Das, Tapas K. [1 ]
机构
[1] Univ S Florida, Dept Ind & Management Syst Engn, Tampa, FL 33620 USA
关键词
BRCA1/2; mutations; hereditary breast and ovarian cancer; intervention strategies; Markov decision process (MDP); COST-EFFECTIVENESS; PREVENTION STRATEGIES; DECISION-ANALYSIS; WOMEN; SURVIVAL; SURGERY; RISK; TOOL;
D O I
10.1109/JBHI.2014.2319246
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Purpose: Women with BRCA1/2 mutations have higher risk for breast and ovarian cancers. Available intervention actions include prophylactic surgeries and breast screening, which vary significantly in cost, cancer prevention, and in resulting death from other causes. We present a model designed to yield optimal intervention strategies for mutation carriers between the ages of 30 and 65 and any prior intervention history. Methods: A Markov decision process (MDP) model is developed that considers yearly state transitions for the mutation carriers and state dependent intervention actions. State is defined as a vector comprising mutation type, health states, prior intervention actions, and age. A discounted value iteration algorithm is used to obtain optimal strategies from the MDP model using both cost and quality-adjusted life years (QALYs) as rewards. Results: The results from MDP model show that for 30-year-old women with BRCA1 mutation and no prior intervention history, the cost-optimal strategy is a combination of prophylactic mastectomy (PM) and prophylactic oophorectomy (PO) at age 30 with no screening afterwards. Whereas, the QALYs-optimal strategy suggests PO at age 30 and PM at age 50 with screening afterwards. For BRCA2 mutation carriers at age 30, the cost-optimal strategy is PO at age 30, PM at age 40, and yearly screening only after age 56. Corresponding QALYs-optimal strategy is PM at age 40 with screening. Strategies for all other ages (31 to 65) are obtained and presented. It is also demonstrated that the cost-optimal strategies offer near maximum survival rate and near minimum cancer incidence rates by age 70, when compared to other ad hoc strategies.
引用
收藏
页码:720 / 727
页数:8
相关论文
共 50 条
  • [41] Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Oden, Lovisa
    Akbari, Mohammad
    Zaman, Tasnim
    Singer, Christian F.
    Sun, Ping
    Narod, Steven A.
    Salmena, Leonardo
    Kotsopoulos, Joanne
    ONCOTARGET, 2016, 7 (52) : 86687 - 86694
  • [42] Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
    Phillips, Kelly-Anne
    Milne, Roger L.
    Rookus, Matti A.
    Daly, Mary B.
    Antoniou, Antonis C.
    Peock, Susan
    Frost, Debra
    Easton, Douglas F.
    Ellis, Steve
    Friedlander, Michael L.
    Buys, Saundra S.
    Andrieu, Nadine
    Nogues, Catherine
    Stoppa-Lyonnet, Dominique
    Bonadona, Valerie
    Pujol, Pascal
    McLachlan, Sue Anne
    John, Esther M.
    Hooning, Maartje J.
    Seynaeve, Caroline
    Tollenaar, Rob A. E. M.
    Goldgar, David E.
    Terry, Mary Beth
    Caldes, Trinidad
    Weideman, Prue C.
    Andrulis, Irene L.
    Singer, Christian F.
    Birch, Kate
    Simard, Jacques
    Southey, Melissa C.
    Olsson, Hakan L.
    Jakubowska, Anna
    Olah, Edith
    Gerdes, Anne-Marie
    Foretova, Lenka
    Hopper, John L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (25) : 3091 - 3099
  • [43] Genetic anticipation of breast cancer among BRCA1/BRCA2 mutation carriers: A retrospective study
    Kedmi, Aviya
    Kadouri, Luna
    Sagy, Iftach
    Hamburger, Tamar
    Levin, Gabriel
    Zimhony-Nissim, Noa
    Peretz, Tamar
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2022, 159 (02) : 537 - 543
  • [44] Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers
    Kuchenbaecker, Karoline B.
    McGuffog, Lesley
    Barrowdale, Daniel
    Lee, Andrew
    Soucy, Penny
    Dennis, Joe
    Domchek, Susan M.
    Robson, Mark
    Spurdle, Amanda B.
    Ramus, Susan J.
    Mavaddat, Nasim
    Terry, Mary Beth
    Neuhausen, Susan L.
    Schmutzler, Rita Katharina
    Simard, Jacques
    Pharoah, Paul D. P.
    Offit, Kenneth
    Couch, Fergus J.
    Chenevix-Trench, Georgia
    Easton, Douglas F.
    Antoniou, Antonis C.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (07):
  • [45] Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers
    Gschwantler-Kaulich, Daphne
    Weingartshofer, Sigrid
    Rappaport-Fuerhauser, Christine
    Zeilinger, Robert
    Pils, Dietmar
    Muhr, Daniela
    Braicu, Elena I.
    Kastner, Marie-Therese
    Tan, Yen Y.
    Semmler, Lorenz
    Sehouli, Jalid
    Singer, Christian F.
    PLOS ONE, 2017, 12 (12):
  • [46] Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers
    Pataky, Reka
    Armstrong, Linlea
    Chia, Stephen
    Coldman, Andrew J.
    Kim-Sing, Charmaine
    McGillivray, Barbara
    Scott, Jenna
    Wilson, Christine M.
    Peacock, Stuart
    BMC CANCER, 2013, 13
  • [47] Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines
    Barac, Ana
    Lynce, Filipa
    Smith, Karen L.
    Mete, Mihriye
    Shara, Nawar M.
    Asch, Federico M.
    Nardacci, Madeline P.
    Wray, Lynette
    Herbolsheimer, Pia
    Nunes, Raquel A.
    Swain, Sandra M.
    Warren, Robert
    Peshkin, Beth N.
    Isaacs, Claudine
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (02) : 285 - 293
  • [48] Anthropometric Measures and Risk of Ovarian Cancer Among BRCA1 and BRCA2 Mutation Carriers
    McGee, Jacob
    Kotsopoulos, Joanne
    Lubinski, Jan
    Lynch, Henry T.
    Rosen, Barry
    Tung, Nadine
    Kim-Sing, Charmaine
    Karlan, Beth
    Foulkes, William D.
    Ainsworth, Peter
    Ghadirian, Parviz
    Senter, Leigha
    Eisen, Andrea
    Sun, Ping
    Narod, Steven A.
    OBESITY, 2012, 20 (06) : 1288 - 1292
  • [49] Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Kotsopoulos, Joanne
    Lubinski, Jan
    Gronwald, Jacek
    Cybulski, Cezary
    Demsky, Rochelle
    Neuhausen, Susan L.
    Kim-Sing, Charmaine
    Tung, Nadine
    Friedman, Susan
    Senter, Leigha
    Weitzel, Jeffrey
    Karlan, Beth
    Moller, Pal
    Sun, Ping
    Narod, Steven A.
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (05) : 1136 - 1146
  • [50] Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers
    Disilvestro, Jessica B.
    Haddad, Jessica
    Robison, Katina
    Beffa, Lindsey
    Laprise, Jessica
    Scalia-Wilbur, Jennifer
    Raker, Christina
    Clark, Melissa A.
    Lokich, Elizabeth
    Hofstatter, Erin
    Dalela, Disha
    Brown, Amy
    Bradford, Leslie
    Toland, Maris
    Stuckey, Ashley
    JOURNAL OF WOMENS HEALTH, 2024, 33 (05) : 624 - 628